Tag: tyrosine kinase inhibitor

IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during...

By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of...

By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly...

By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 In the twentieth century, adjuvant chemotherapy became the standard of care for resected NSCLC...